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Oral Azithromycin for Treatment of Intractable Rosacea
Rosacea is a common chronic cutaneous disorder that primarily occurs on the convex 
surfaces of the central face and is often characterized by exacerbations and remissions. A 
case of a 52-yr-old woman visited our clinic in February 2008 complaining typical features 
of rosacea including multiple pinhead to rice-sized erythematous papules. We applied 
various conventional treatments including topical benzoyl peroxide and metronidazole as 
well as oral metronidazole, isotretinoin, and doxycycline. The lesions were not controlled 
but were rather aggravated by complications from these treatments. Therefore, we 
prescribed oral azithromycin, which has anti-inflammatory effects and reduces reactive 
oxygen species. Ten weeks after the administration of oral azithromycin, 500 mg per day 
for 2 weeks, the lesions had mostly disappeared and no specific side effects related to the 
azithromycin were noted. Oral azithromycin dosing 500 mg/day for 2 weeks is effective for 
treatment of intractable rosacea.
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CASE REPORT
Dermatology
INTRODUCTION
Rosacea is a common skin disease characterized by transient or 
persistent central facial erythema, visible blood vessels, and fre-
quently, papules and pustules. Treatment of rosacea is usually 
based on a combination of systemic and topical antibiotics. Since 
the 1950’s, tetracycline and erythromycin are the most common-
ly used oral antibiotics (1-3). However, long-term treatment with 
antibiotics is not well tolerated because of side-effects includ-
ing gastrointestinal intolerance, photosensitivity and candidia-
sis (3). Moreover, given the chronic nature of the disease, there 
is a possibility of developing bacterial resistance (1). Azithromy-
cin is a newly developed macrolide which offers some advan-
tages compared to previously used antibiotics (4). It has unique 
pharmacokinetics that maintains prolonged tissue levels and 
allows less frequent dosage. Fernandez-Obregon (5) reported 
that all of ten patients who were not tolerated or controlled by 
conventional treatment demonstrated a significant improve-
ment with the oral use of azithromycin. After then, azithromy-
cin has been found to be effective in the intractable rosacea in 
several clinical reports (1, 6, 7).
   We report a case of a 52-yr-old rosacea patient who was re-
fractory and complicated by reactions to conventional topical 
and oral medications. After 10 weeks of oral azithromycin, her 
lesions had mostly disappeared and the patient suffered no spe-
cific side-effects related to the medication. Our case showed that 
oral azithromycin could be a viable new treatment option for 
intractable rosacea cases.
CASE DESCRIPTION
A 52-yr-old postmenopausal woman complained of a 10-month 
history of multiple erythematous papules and some pustules 
on both cheeks on February 11, 2008 (Fig. 1). The lesions were 
characterized by progressive extension and continuous flush-
ing. There was neither a familial history of similar lesions nor 
previous significant medical history. Physical examination re-
vealed multiple pinhead to rice-sized erythematous papules and 
pustules on both cheeks. Laboratory studies including complete 
blood cell count (CBC), blood chemistry, and anti-nuclear anti-
body (ANA) were within normal limits. More than ten demodex 
mites were observed on the demodex study. On the standard 
patch test, only nickel sulfate showed a positive response.
  On the basis of medical history and clinical findings, the pa-
tient was diagnosed as rosacea. However, her skin lesions were 
not controlled by topical application of benzoyl peroxide, met-
ronidazole twice a day or crotamiton once a day, or oral admin-
istration of doxycycline 200 mg for a month, metronidazole 500 
mg for two weeks or isotretinoin 10 mg for a month. Rather her 
rosacea was aggravated or complicated by these medications. 
After taking conventional treatment of rosacea, she complained 
of diffuse facial erythema, swelling and aggravated papules (Fig. 
2). We then prescribed oral azithromycin, which has both anti-
inflammatory effects and leads to a reduction in reactive oxy-
gen species. Two weeks after oral administration of 500 mg per 
day of azithromycin, facial erythema and swelling was reduced. 
Since then, papular lesions which are presented on the cheek 
were begun to decrease. After 10 weeks of oral azithromycin, the Kim J-H, et al.  •  Oral Azithromycin for Treatment of Intractable Rosacea
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lesions had mostly disappeared, and no specific side-effects re-
lated to the medication were noted (Fig. 3). Also until 6 months 
after treatment, the patient had not experienced any recurrence 
or aggravation. This patient provided informed written consent 
prior to usage of her photographs.
DISCUSSION
Rosacea is a common cutaneous disorder which occurs most 
frequently in light-skinned middle aged women. There are vari-
able cutaneous signs of rosacea such as flushing, erythema, tel-
angiectasia, edema, papules and pustules (2).
  While the pathogenesis of rosacea remains unknown, several 
Fig. 1. Multiple pinhead to rice-sized erythe-
matous papules, typical features of rosacea, 
were present on both cheeks.
Fig. 2. The patient’s skin lesions were not 
controlled by conventional treatments for 
rosacea, but rather, were aggravated.
Fig. 3. Ten weeks after taking oral azithro-
mycin, the patient’s skin lesions had mostly 
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factors have been implicated including inherent abnormalities in 
cutaneous vascular homeostasis and dysregulated thermal mech-
anisms. Recent reports suggest that the effects of reactive oxy-
gen species can contribute to the development of rosacea (8).
  Conventional treatment of rosacea is based on a combination 
of systemic and topical antibiotics. Since the 1950’s, tetracycline 
and erythromycin are the most commonly used oral antibiotics 
(1-3). The therapeutic activity of commonly used antimicrobials 
including tetracycline, doxycycline has been mainly attributed 
to their anti-inflammatory activities (9, 10). These results indi-
cate that antibiotics used in the treatment of rosacea affect vari-
ous inflammatory processes such as the migration of neutro-
phils, production of pro-inflammatory cytokines including in-
terleukin-1, 6, 8, 10, tumor necrosis factor-α, leukotriene B4, and 
oxidative burst in phagocytes (11-13). Topical metronidazole 
and oral tetracyclines effectively treat about 80%-90% of rosa-
cea patients (6). However, long-term treatment with antibiotics 
is not well tolerated due to requiring frequent administration, 
poor compliances and side-effects including gastrointestinal 
intolerance, photosensitivity and candidiasis (5, 7). In addition, 
some patients do not respond to variable combination therapies 
and rather aggravated by their complications. Modi et al. (1) re-
ported a rosacea patient who were developed tense bullae and 
hypopigmented scarring after taking oral doxycycline 100 mg. 
  Oral azithromycin is a newly developed macrolide which of-
fers some advantages over previously used antibiotics. It has 
unique pharmacokinetics that allows it to penetrate into intra-
cellular compartments rapidly and maintain prolonged tissue 
levels. This allows for less frequent application and shorter du-
ration of treatment which may increase compliance. With its 
high affinity for inflammatory tissues, azithromycin can achieve 
steady state tissue levels in approximately 72-96 hr (14). More-
over, after administration of oral azithromycin, tissue reactive 
oxygen species, an etiologic factor in the development of rosa-
cea, were greatly decreased in some cases (7). 
  The utility of oral azithromycin was confirmed by several clin-
ical studies. Fernandez-Obregon (5) reported that all of ten pa-
tients who were not tolerated or controlled by conventional treat-
ment of rosacea demonstrated a significant improvement with 
the oral use of azithromycin. In addition, Modi et al. (1) treated 
a 67-yr old man who had photosensitivity to the doxycycline 
and hyperpigmented dyschromia to the minocycline with an 
oral use of azithromycin in a dose of 250 mg 3 times weekly. Ba-
kar et al. (4) reported that treatment with oral azithromycin led 
to 75% decreases in the total number of lesions and an 89% de-
crease in inflammatory lesions compared with basal status. An-
other open-label study showed that azithromycin is as effective 
as standard dose of doxycycline and has a positive impact on 
the quality of life of patients compared with conventional treat-
ment regimens (15). 
  Azithromycin may also be an acceptable agent for those using 
other medications, because it has no known major drug inter-
actions. Additionally, azithromycin shows lower incidences of 
gastrointestinal discomfort compared with erythromycin (16). 
According to one clinical study, only two of 32 patients com-
plained of mild gastric discomfort and no one withdrew from 
the study due to the side-effects of aztithromycin (17). In our case, 
there were no specific side-effects related to the medication.
  In summary, we report a case of a 52-yr-old woman who pre-
sented with intractable multiple, pinhead to rice-sized erythem-
atous papules on her face, which were controlled by oral azithro-
mycin. Our case shows that azithromycin could be a new treat-
ment option for the treatment of intractable rosacea.
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